Hormonal
A 1.5-year combined lifestyle intervention (normocaloric diet, exercise, CBT) inducing modest weight loss (~5%) normalizes long-term adiposity hormones (leptin, insulin, adiponectin) without triggering orexigenic short-term appetite signals, thereby avoiding the hormonal drive for weight regain typically seen with severe caloric restriction.
To maintain weight loss without triggering intense hunger, focus on a sustainable, healthy diet rather than severe calorie restriction. Combine this with regular mixed exercise (aerobic and resistance) and behavioral strategies (like CBT) over a long period (1.5 years). This approach normalizes metabolic hormones without activating strong hunger signals, making long-term maintenance more feasible than with crash diets.
CLI-induced weight loss was associated with changes in levels of long-term adiposity-related hormones towards healthy levels, but not with orexigenic changes in most short-term appetite signals. Our data indicates that the clinical impact of alterations in appetite-regulating hormones during modest weight loss remains questionable.
Why this rating
Randomized controlled trial design (implied by intervention study), large sample for this niche (n=39), long follow-up (1.5 years), but observational correlation for hormone-predictive claims.
Source
Levels of hormones regulating appetite and energy homeostasis in response to a 1.5-Year combined lifestyle intervention for obesity
Susanne Kuckuck et al. · Frontiers in Physiology · 2023
DOI 10.3389/fphys.2023.1010858
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →